EP Patent

EP3728228A1 — Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors

Assigned to Hibercell Inc · Expires 2020-10-28 · 6y expired

What this patent protects

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

USPTO Abstract

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described herein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3728228A1
Jurisdiction
EP
Classification
—
Expires
2020-10-28
Drug substance claim
No
Drug product claim
No
Assignee
Hibercell Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.